|Conference Call Information|
|Dial-in numbers:||+1 (855) 219-9219 (|
|Live webcast:||www.retrophin.com in the "Events & Presentations" section of the "Investors" page|
A replay of the call will be available from
Retrophin is a fully integrated biopharmaceutical company dedicated to delivering life-changing therapies to people living with rare diseases who have few, if any, treatment options. The Company's approach centers on its pipeline featuring late-stage candidates targeting rare diseases with significant unmet medical needs, including sparsentan for focal segmental glomerulosclerosis (FSGS), a disorder characterized by progressive scarring of the kidney often leading to end-stage renal disease, and RE-024 for pantothenate kinase-associated neurodegeneration (PKAN), a life-threatening neurological disorder that typically begins in early childhood. Research exploring the potential of early-stage assets in several rare diseases is also underway. Retrophin's R&D efforts are supported by revenues from the Company's commercial products, Thiola®, Cholbam®, and Chenodal®.
Chris Cline, CFA Vice President, Investor Relations & Corporate Communications 646-564-3680 IR@retrophin.com
News Provided by Acquire Media